+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biopharmaceuticals Contract Manufacturing Market - Global Forecast 2026-2032- Product Image
Biopharmaceuticals Contract Manufacturing Market - Global Forecast 2026-2032- Product Image
Sale

Biopharmaceuticals Contract Manufacturing Market - Global Forecast 2026-2032

  • Report

  • 191 Pages
  • July 2026
  • Region: Global
  • 360iResearch™
  • ID: 5613012
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biopharmaceuticals Contract Manufacturing Market is projected to reach USD 64.68 Billion in 2026. It is expected to continue growing at a CAGR of 11.41%, reaching USD 124.11 Billion by 2032.

Biopharmaceuticals contract manufacturing has become a strategic pillar for drug developers seeking scalable capacity, specialized technical expertise, and compliant production across biologics, vaccines, biosimilars, cell therapies, gene therapies, and advanced protein-based medicines. As biologic pipelines expand and product modalities become more complex, outsourcing partners are increasingly involved from cell line development and process optimization through clinical supply, commercial manufacturing, fill-finish, packaging, analytical testing, and regulatory support. The sector is shaped by strict current good manufacturing practice requirements, rising adoption of single-use bioprocessing, stronger quality-by-design expectations, and the need for resilient global supply chains. Verified regulatory and public health priorities consistently point to the same imperatives: validated processes, robust contamination control, traceable raw materials, reliable cold-chain handling, and inspection-ready quality systems. For industry leaders, competitive advantage now rests on flexible manufacturing networks, digital process control, rapid technology transfer, and the ability to support both high-volume biologics and small-batch personalized therapies without compromising quality, traceability, or regulatory readiness.

Transformative Shifts Reshaping the Outsourcing Landscape

The biopharmaceuticals contract manufacturing landscape is undergoing structural change as demand shifts from conventional biologics toward more diverse and technically demanding modalities. Manufacturers are expanding capabilities in mammalian cell culture, microbial fermentation, high-potency biologics handling, viral vector production, mRNA-related workflows, aseptic fill-finish, and cold-chain-enabled distribution. Single-use systems are reducing changeover time and cross-contamination risk, while modular facilities are improving responsiveness for clinical and commercial programs. Regulatory authorities continue to emphasize data integrity, process validation, environmental monitoring, sterile assurance, and supply chain transparency, pushing contract manufacturers to strengthen digital quality systems and end-to-end documentation. At the same time, geopolitical uncertainty, pandemic-era lessons, medicine security policies, and regional biomanufacturing incentives are encouraging nearshoring, dual sourcing, and localized production strategies. The result is a more distributed, technology-intensive outsourcing ecosystem where speed, compliance, flexibility, and scientific depth are as important as production capacity.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing biopharmaceuticals contract manufacturing by improving process understanding, operational efficiency, quality oversight, and decision-making. AI-enabled analytics can support cell culture optimization, media formulation assessment, deviation detection, predictive maintenance, batch performance modeling, and real-time release strategies when combined with validated data governance frameworks. Machine learning tools are also helping analyze large volumes of process analytical technology data, environmental monitoring records, and quality control outputs to identify patterns that may not be visible through conventional review. In manufacturing operations, AI can contribute to scheduling optimization, capacity planning, raw material risk assessment, and automated documentation workflows. However, adoption must remain aligned with regulatory expectations for validation, explainability, cybersecurity, audit trails, and human oversight, including principles reflected in global good manufacturing practice and computerized systems guidance. The cumulative impact of AI is not the replacement of scientific and quality expertise but the elevation of process control, faster root-cause analysis, reduced operational variability, and stronger readiness for increasingly complex biologic production models.

Key Regional Insights in Contract Biomanufacturing

Asia-Pacific is strengthening its role in biopharmaceuticals contract manufacturing through expanding biologics infrastructure, government support for local pharmaceutical production, and growing clinical development activity across China, India, Japan, South Korea, Australia, and Southeast Asia. The region benefits from a large skilled scientific workforce, improving regulatory maturity, and rising investment in biosimilars, vaccines, cell therapy, sterile manufacturing, and technology transfer. Europe continues to be a leading center for high-quality biologics manufacturing, supported by mature regulatory oversight, specialized technical talent, and strong capabilities in aseptic processing, biosimilars, vaccines, and advanced therapies across major EU economies and the United Kingdom. North America remains a critical hub due to its advanced biopharma innovation base, established regulatory framework, deep clinical pipeline, and demand for high-compliance commercial biologics production, particularly in the United States and Canada. Latin America is advancing gradually as governments and health systems prioritize vaccine security, local biologics availability, and technology transfer, with Brazil and Mexico playing central roles in regional pharmaceutical manufacturing. Africa is at an earlier stage but is gaining policy attention due to vaccine manufacturing priorities, public health security objectives, and regional efforts to strengthen pharmaceutical self-sufficiency, creating long-term opportunities for workforce development, regulatory capacity building, and compliant local production. The Middle East is increasing biomanufacturing relevance through healthcare diversification initiatives, life sciences industrialization, and demand for regional supply resilience, particularly in Gulf economies where pharmaceutical localization and hospital system modernization are becoming strategic priorities.

Key Group Insights for Manufacturing Strategies

NATO member countries, while not a commercial bloc, represent a strategically significant network for supply chain resilience, biosecurity preparedness, and healthcare infrastructure coordination, reinforcing interest in secure manufacturing capacity, redundant supply sources, and reliable access to critical biologic medicines. G7 countries continue to anchor high-value contract manufacturing demand through strong innovation ecosystems, rigorous quality expectations, advanced regulatory agencies, and concentration of originator biologics, vaccines, and advanced therapy development. BRICS countries are central to global manufacturing resilience because they combine large patient populations, expanding domestic pharmaceutical industries, growing biologics pipelines, and policy support for local production, biosimilars, and technology transfer. The European Union remains highly influential due to its harmonized regulatory system, strong pharmacovigilance framework, advanced biomanufacturing workforce, and established demand for biosimilars, sterile biologics, and advanced therapy production. ASEAN is emerging as an important group for biopharmaceuticals contract manufacturing as member economies expand healthcare access, attract pharmaceutical investment, and improve regulatory cooperation for biologics and vaccines. The GCC is prioritizing life sciences localization as part of broader economic diversification, with emphasis on pharmaceutical security, hospital demand, cold-chain infrastructure, and strategic manufacturing partnerships.

Key Country Insights Across Leading Markets

China has rapidly expanded biologics and cell therapy manufacturing capability, supported by domestic innovation, regulatory modernization, and growing demand for outsourced development and manufacturing services. The United States leads demand for sophisticated biopharmaceuticals contract manufacturing due to its extensive biologics pipeline, advanced regulatory environment, and concentration of clinical-stage and commercial drug development. Japan maintains strength in high-quality biologics manufacturing, regulatory discipline, and specialty therapeutics, while India is a major force in biosimilars, vaccines, process development, and cost-efficient pharmaceutical production with increasing emphasis on global quality standards. Germany is recognized for high-quality pharmaceutical engineering, automation, sterile processing, and biologics production capabilities, while the United Kingdom continues to be important for advanced therapies, biologics research, clinical manufacturing expertise, and translational science infrastructure. Australia supports clinical biomanufacturing, early-stage development, and regional research collaboration, and France contributes through strong vaccine, sterile manufacturing, and life sciences infrastructure. South Korea has become a major Asia-Pacific biomanufacturing hub, with strong expertise in large-scale biologics production, biosimilars, and advanced facility execution. Italy and Spain both play meaningful roles in European sterile production, fill-finish, and pharmaceutical manufacturing services. Canada supports the ecosystem through investments in biologics, vaccine capacity, and life sciences innovation, while Russia’s biopharmaceutical manufacturing landscape is shaped by domestic supply priorities and localization policies. Brazil remains Latin America’s most prominent biologics manufacturing market, supported by public health programs, technology transfer initiatives, and biosimilar interest, while Mexico is gaining relevance as a nearshoring destination for pharmaceutical supply chain support, packaging, and regional healthcare demand.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize manufacturing flexibility, regulatory readiness, and supply chain resilience as core strategic imperatives. Contract manufacturing organizations and biopharma sponsors should invest in modular capacity, single-use technologies, advanced analytics, validated digital quality systems, and robust contamination control strategies. Technology transfer should be treated as a disciplined, data-driven process supported by standardized documentation, defined process parameters, method comparability, and early alignment between development and manufacturing teams. Leaders should also diversify critical raw material sources, qualify secondary suppliers, and strengthen cold chain and sterile logistics planning for sensitive biologics and advanced therapies. AI and automation should be deployed selectively in areas where data integrity, validation, auditability, and cybersecurity can be ensured. Workforce development is equally important, particularly in aseptic processing, bioprocess engineering, quality assurance, regulatory affairs, analytical testing, and advanced therapy manufacturing. Strategic partnerships should be evaluated not only on cost but also on technical capability, inspection readiness, quality culture, scalability, lifecycle support, and ability to move programs from clinical batches to commercial supply.

Research Methodology for Evidence-Based Insights

This executive summary is developed through a structured secondary research approach focused on verified industry, regulatory, scientific, and public policy sources. The methodology emphasizes triangulation of information from regulatory authority guidance, public health agency publications, peer-reviewed scientific literature, clinical development trends, manufacturing technology documentation, trade policy updates, and official government initiatives related to biologics and pharmaceutical production. Insights are assessed through qualitative validation across multiple credible sources to identify consistent patterns in technology adoption, regional manufacturing development, regulatory expectations, outsourcing strategies, and supply chain priorities. Particular attention is given to good manufacturing practice requirements, data integrity principles, biologics quality guidance, sterile manufacturing expectations, vaccine security initiatives, and advanced therapy production considerations. The analysis excludes market sizing, revenue estimation, market share calculation, and forecasting to maintain focus on evidence-based strategic interpretation. The research framework prioritizes data integrity, source credibility, current regulatory relevance, and practical applicability for stakeholders operating in biopharmaceuticals contract manufacturing.

Conclusion: Strategic Outlook for Contract Manufacturing

Biopharmaceuticals contract manufacturing is moving from a capacity outsourcing model toward a strategic partnership model defined by scientific specialization, regulatory excellence, digital maturity, and global supply resilience. As biologic modalities diversify and manufacturing requirements become more complex, success will depend on the ability to combine flexible production platforms with rigorous quality systems, validated digital tools, and responsive technology transfer. Regionalization, AI-enabled process intelligence, single-use bioprocessing, advanced therapy manufacturing, and stronger supply assurance are reshaping how sponsors select partners and how manufacturers design future-ready operations. Organizations that invest in compliant innovation, skilled talent, resilient supplier networks, transparent quality governance, and inspection-ready execution will be best positioned to support the next generation of biologics, biosimilars, vaccines, and personalized medicines.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Biopharmaceuticals Contract Manufacturing Market, by Service Type
7.1. Introduction
7.2. Analytical & Quality Control Testing
7.3. Biologics Manufacturing Service
7.4. Process Development & Optimization
8. Biopharmaceuticals Contract Manufacturing Market, by Product Type
8.1. Introduction
8.2. Cell And Gene Therapy
8.2.1. CAR T Therapy
8.2.2. Gene Editing Therapy
8.3. Monoclonal Antibodies
8.4. Recombinant Proteins
8.4.1. Enzymes
8.4.2. Hormones
8.5. Vaccines
8.5.1. mRNA Vaccines
8.5.2. Protein Subunit Vaccines
8.5.3. Viral Vector Vaccines
9. Biopharmaceuticals Contract Manufacturing Market, by Production Stage
9.1. Introduction
9.2. Clinical
9.2.1. Phase I
9.2.2. Phase II
9.2.3. Phase III
9.3. Commercial
10. Biopharmaceuticals Contract Manufacturing Market, by Organisation Size
10.1. Introduction
10.2. Large Organisation
10.3. Small & Medium Organisation
11. Biopharmaceuticals Contract Manufacturing Market, by Application
11.1. Introduction
11.2. Autoimmune Disorders
11.3. Cardiovascular
11.4. Infectious Diseases
11.4.1. Bacterial
11.4.2. Parasitic
11.4.3. Viral
11.5. Neurology
11.6. Oncology
12. Biopharmaceuticals Contract Manufacturing Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Biopharmaceuticals Contract Manufacturing Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Biopharmaceuticals Contract Manufacturing Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Aenova Holding GmbH
16.3. AGC Biologics
16.4. Ajinomoto Co., Inc.
16.5. Binex Co., Ltd.
16.6. BioVectra Inc.
16.7. Boehringer Ingelheim International GmbH
16.8. BSP Pharmaceuticals S.p.A.
16.9. Cambrex Corporation
16.10. Catalent, Inc.
16.11. CordenPharma International GmbH
16.12. Cytovance Biologics, Inc.
16.13. Emergent BioSolutions Inc.
16.14. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
16.15. GenScript Biotech Corporation
16.16. IDT Biologika GmbH
16.17. Jubilant Pharmova Limited
16.18. KBI Biopharma, Inc.
16.19. Lonza Group AG
16.20. Piramal Pharma Limited
16.21. ProBioGen AG
16.22. Recipharm AB
16.23. Rentschler Biopharma SE
16.24. Samsung Biologics Co., Ltd.
16.25. Siegfried Holding AG
16.26. ST Pharm Co., Ltd.
16.27. Thermo Fisher Scientific Inc.
16.28. ThermoGenesis Holdings, Inc.
List of Figures
FIGURE 1. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANALYTICAL & QUALITY CONTROL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANALYTICAL & QUALITY CONTROL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANALYTICAL & QUALITY CONTROL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL BIOLOGICS MANUFACTURING SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS MANUFACTURING SERVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS MANUFACTURING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PROCESS DEVELOPMENT & OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PROCESS DEVELOPMENT & OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PROCESS DEVELOPMENT & OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CELL AND GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CELL AND GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CELL AND GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CAR T THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CAR T THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CAR T THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GENE EDITING THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GENE EDITING THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GENE EDITING THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ENZYMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ENZYMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ENZYMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL HORMONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL HORMONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MRNA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MRNA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PROTEIN SUBUNIT VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PROTEIN SUBUNIT VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PROTEIN SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL COMMERCIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL COMMERCIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL COMMERCIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL LARGE ORGANISATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL LARGE ORGANISATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL LARGE ORGANISATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL SMALL & MEDIUM ORGANISATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SMALL & MEDIUM ORGANISATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL SMALL & MEDIUM ORGANISATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PARASITIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL PARASITIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL PARASITIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 107. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 109. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 110. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 112. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 113. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 114. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 115. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 116. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 140. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 141. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 142. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 143. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 144. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 145. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 146. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 147. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 148. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 149. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 150. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 163. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 164. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 165. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 166. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 167. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 168. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 169. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 170. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 171. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 172. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 173. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 174. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 175. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 176. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 177. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 178. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 179. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 180. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 181. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 182. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 183. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 184. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 185. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 186. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 187. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 188. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 189. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 190. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 191. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 192. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 193. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 194. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 195. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 207. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 208. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 209. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 210. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 211. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 212. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 213. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 214. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 215. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 216. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 217. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 218. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 219. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 220. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 221. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 222. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 223. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 224. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 225. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 226. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 227. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 228. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 229. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 230. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 231. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 232. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 233. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 234. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 235. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 236. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 237. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 238. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 239. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 240. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 241. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 242. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 243. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 246. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 252. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 253. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 254. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 255. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 256. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 257. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 258. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 259. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 260. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 261. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 262. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 263. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 264. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 265. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 266. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 267. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 268. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 269. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 270. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 271. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 272. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 273. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 274. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 275. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 276. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 277. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 278. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 279. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 280. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 281. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 282. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 283. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 284. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 293. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 294. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 295. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 296. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 297. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 298. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 299. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 300. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
TABLE 301. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 302. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 303. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
TABLE 304. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
TABLE 305. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 306. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 307. FRANCE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-20

Companies Mentioned

  • AbbVie Inc.
  • Aenova Holding GmbH
  • AGC Biologics
  • Ajinomoto Co., Inc.
  • Binex Co., Ltd.
  • BioVectra Inc.
  • Boehringer Ingelheim International GmbH
  • BSP Pharmaceuticals S.p.A.
  • Cambrex Corporation
  • Catalent, Inc.
  • CordenPharma International GmbH
  • Cytovance Biologics, Inc.
  • Emergent BioSolutions Inc.
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • GenScript Biotech Corporation
  • IDT Biologika GmbH
  • Jubilant Pharmova Limited
  • KBI Biopharma, Inc.
  • Lonza Group AG
  • Piramal Pharma Limited
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics Co., Ltd.
  • Siegfried Holding AG
  • ST Pharm Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • ThermoGenesis Holdings, Inc.

Table Information

Report AttributeDetails
No. of Pages191
PublishedJuly 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 64.68 Billion
Forecasted Market Value ( USD ) by 2032 $ 124.11 Billion
Compound Annual Growth Rate11.4%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Biopharmaceutical CMO & CRO Market - Global Forecast 2026-2032 - Product Image

Biopharmaceutical CMO & CRO Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Biopharmaceutical Third Party Logistics Market - Global Forecast 2026-2032 - Product Image

Biopharmaceutical Third Party Logistics Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Biopharmaceutical Fermentation Systems - Global Strategic Business Report - Product Image

Biopharmaceutical Fermentation Systems - Global Strategic Business Report

  • Report
  • 224 Pages
  • Global
From
Biopharmaceutical CMO and CRO - Global Strategic Business Report - Product Image

Biopharmaceutical CMO and CRO - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From
Biopharmaceutical Contract Manufacturing Market by Service (Manufacturing, Fill-Finish), Type (Drug Substance, Drug Product), Scale (Clinical), Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2030 - Product Image

Biopharmaceutical Contract Manufacturing Market by Service (Manufacturing, Fill-Finish), Type (Drug Substance, Drug Product), Scale (Clinical), Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2030

  • Report
  • 383 Pages
  • Global
From

About the Biopharmaceutical Contract Manufacturing Market

Biopharmaceutical Contract Manufacturing (CMO) is a service provided by specialized companies to biopharmaceutical companies. CMOs provide a range of services, from drug development and manufacturing to packaging and distribution. These services are tailored to the specific needs of the biopharmaceutical company, allowing them to focus on their core competencies. CMOs are able to provide a wide range of services, including process development, analytical testing, clinical trial materials, and commercial manufacturing. They also provide regulatory support, helping biopharmaceutical companies to navigate the complex regulatory landscape. CMOs are an important part of the biopharmaceutical industry, providing a cost-effective and efficient way to develop and manufacture drugs. Companies in the market include Lonza, Patheon, Boehringer Ingelheim, Catalent, and Ajinomoto Bio-Pharma Services. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.